-
Tytuł:
-
State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
-
Autorzy:
-
Singh N; Tom Baker Cancer Centre, Gynecologic Oncology , Calgary, Alberta, Canada.
Badrun D; Tom Baker Cancer Centre, Gynecologic Oncology , Calgary, Alberta, Canada.
Ghatage P; Tom Baker Cancer Centre, Gynecologic Oncology , Calgary, Alberta, Canada.
-
Źródło:
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Sep; Vol. 21 (13), pp. 1579-1590. Date of Electronic Publication: 2020 Jun 17.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : Informa Healthcare
Original Publication: London : Ashley Publications, c1999-
-
MeSH Terms:
-
Angiogenesis Inhibitors/*therapeutic use
Bevacizumab/*therapeutic use
Carcinoma, Ovarian Epithelial/*drug therapy
Neovascularization, Pathologic/*drug therapy
Ovarian Neoplasms/*drug therapy
Carcinoma, Ovarian Epithelial/blood supply ; Carcinoma, Ovarian Epithelial/mortality ; Clinical Trials as Topic ; Female ; Humans ; Ovarian Neoplasms/blood supply ; Ovarian Neoplasms/mortality ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Treatment Outcome
-
Contributed Indexing:
-
Keywords: Angiogenesis inhibitors; aflibercept; bevacizumab; cediranib; nintedanib; ovarian cancer; pazopanib; sorafenib; sunitinib
-
Substance Nomenclature:
-
0 (Angiogenesis Inhibitors)
0 (Poly(ADP-ribose) Polymerase Inhibitors)
2S9ZZM9Q9V (Bevacizumab)
-
Entry Date(s):
-
Date Created: 20200620 Date Completed: 20200914 Latest Revision: 20200914
-
Update Code:
-
20240105
-
DOI:
-
10.1080/14656566.2020.1775813
-
PMID:
-
32552175
-
Angiogenesis inhibitors have clearly shown activity in ovarian cancer in various settings; however, preliminary data did not reflect significant survival benefit. Bevacizumab has been extensively studied and is approved for use in ovarian malignancy. However, the efficacy of bevacizumab is modest and most treated patients eventually develop acquired resistance, which highlights the need for new targeted therapies and/or combination strategies. Newer therapies are being evaluated and their role of these newer therapies is upcoming and promising. Recent research focuses on the role of this drug group in frontline, maintenance and recurrent settings. Combination of PARP inhibitors with angiogenesis inhibitors has recently shown to improved survival rates. Potential strategies need to be devised for selecting patients most likely to benefit from such therapy.